Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Lancora Ivabradine Heart failure, NYHA class II or III Reimburse with clinical criteria and/or conditions Complete
Lantus Insulin glargine (rDNA origin) Diabetes mellitus, Type 1 & 2 Do not list Complete
Lantus Insulin glargine (rDNA origin) Diabetes mellitus, Type 1 & 2 Do not list Complete
Lantus Insulin glargine (rDNA origin) Diabetes mellitus, Type 1 & 2 N/A Complete
Lapelga Pegfilgrastim Febrile neutropenia N/A Complete
Lartruvo Olaratumab Advanced Soft Tissue Sarcoma Reimburse with clinical criteria and/or conditions Complete
Latuda Lurasidone Schizophrenia Do not list Complete
Latuda Lurasidone Schizophrenia List with criteria/condition Complete
Latuda lurasidone Bipolar I disorder Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Lazcluze and Rybrevant lazertinib and amivantamab Locally advanced or metastatic non-small cell lung cancer (NSCLC) Pending